Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact.

Johnston SS, Udall M, Cappelleri JC, Johnson BH, Shrady G, Chu BC, Silverman SL.

Pain Med. 2014 Aug;15(8):1282-93. doi: 10.1111/pme.12330.

2.

Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine.

Johnston SS, Udall M, Cappelleri JC, Johnson BH, Shrady G, Chu BC, Silverman SL.

Am J Health Syst Pharm. 2013 Dec 15;70(24):2207-17. doi: 10.2146/ajhp130088.

PMID:
24296843
3.

Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine.

Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R.

Pain Pract. 2012 Jan;12(1):14-22. doi: 10.1111/j.1533-2500.2011.00470.x.

PMID:
21615857
4.

Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.

Sun P, Peng X, Sun S, Novick D, Faries DE, Andrews JS, Wohlreich MM, Wu A.

Pain Pract. 2014 Jan;14(1):22-31. doi: 10.1111/papr.12044.

PMID:
23489659
5.

Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia.

Zhao Y, Sun P, Watson P, Mitchell B, Swindle R.

Pain Pract. 2011 May-Jun;11(3):204-16. doi: 10.1111/j.1533-2500.2010.00412.x.

PMID:
20807351
6.

Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.

Gore M, Tai KS, Chandran A, Zlateva G, Leslie D.

J Med Econ. 2012;15(1):19-31. doi: 10.3111/13696998.2011.629262.

PMID:
21970699
7.

Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.

Harnett J, Margolis J, Cao Z, Fowler R, Sanchez RJ, Mardekian J, Silverman SL.

Pain Pract. 2011 May-Jun;11(3):217-29. doi: 10.1111/j.1533-2500.2010.00440.x.

PMID:
21199319
8.

Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia.

Sun P, Zhao Y, Zhao Z, Watson P.

Curr Med Res Opin. 2011 Sep;27(9):1793-801. doi: 10.1185/03007995.2011.605113.

PMID:
21810060
9.

Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.

Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R.

Pain Pract. 2012 Mar;12(3):209-18. doi: 10.1111/j.1533-2500.2011.00478.x.

PMID:
21676163
10.

Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.

Zhao Y, Sun P, Watson P.

Curr Med Res Opin. 2011 Apr;27(4):785-92. doi: 10.1185/03007995.2011.554807.

PMID:
21303196
11.

Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia.

Kim SC, Landon JE, Lee YC.

Arthritis Res Ther. 2015 Jan 28;17:18. doi: 10.1186/s13075-015-0530-8.

12.

Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine.

Margolis J, Cao Z, Fowler R, Harnett J, Sanchez RJ, Mardekian J, Silverman SL.

J Med Econ. 2010;13(4):738-47. doi: 10.3111/13696998.2010.535878.

PMID:
21091395
13.

Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia.

Peng X, Sun P, Novick D, Andrews J, Sun S.

J Pain Res. 2014 Jan 9;7:37-46. doi: 10.2147/JPR.S51636.

14.

Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia.

Ellis JJ, Sadosky AB, Ten Eyck LL, Cappelleri JC, Brown CR, Suehs BT, Parsons B.

Clinicoecon Outcomes Res. 2014 Oct 14;6:389-99. doi: 10.2147/CEOR.S66759.

15.

Predictors of pain medication selection among patients diagnosed with fibromyalgia.

Boulanger L, Wu N, Chen SY, Nagar S, Fraser K, Bernauer MJ, Zhao Z, Zhao Y.

Pain Pract. 2012 Apr;12(4):266-75. doi: 10.1111/j.1533-2500.2011.00497.x.

PMID:
21899718
16.

Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin.

Gore M, Sadosky AB, Zlateva G, Clauw DJ.

Pain Pract. 2009 Sep-Oct;9(5):363-74. doi: 10.1111/j.1533-2500.2009.00292.x.

PMID:
19500273
17.

Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.

Udall M, Louder A, Suehs BT, Cappelleri JC, Joshi AV, Patel NC.

J Med Econ. 2013;16(6):784-92. doi: 10.3111/13696998.2013.793692.

PMID:
23565813
18.

A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.

Ellis JJ, Sadosky AB, Ten Eyck LL, Mudumby P, Cappelleri JC, Ndehi L, Suehs BT, Parsons B.

BMC Health Serv Res. 2015 Apr 15;15:159. doi: 10.1186/s12913-015-0829-9.

19.
20.

Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.

Choy E, Richards S, Bowrin K, Watson P, Lloyd A, Sadosky A, Zlateva G.

Curr Med Res Opin. 2010 Apr;26(4):965-75. doi: 10.1185/03007991003600271.

PMID:
20178405
Items per page

Supplemental Content

Support Center